## Index

### A

Abbreviated New Drug Application (ANDA), litigation, 59–73

ACIP. See Advisory Council on Intellectual Property

Acromed Corp. v. Sofamor Danek Group, Inc., 84, 87–88

Advisory Council on Intellectual Property (ACIP), 232

Aerospace America, Inc. v. Abatement Technologies, Inc., 3

AIA. See America Invents Act

Ajinomoto Co., Inc. v. Archer-Daniels-Midland Co., 6

Akamai Technologies, Inc. v. Limelight Networks, Inc., 186

Altana PharmaAG v. Tevs Pharms. USA, Inc., 112

America Invents Act (AIA)

CREATE Act expansion, 23–27

disclosure and claiming requirements

claim requirements in Section 112, 12–13

overview, 10

specification requirements in Section 112, 10–12

first-inventor-to-file, 16–17

inventorship, 90

nonobviousness of invention, 9–10, 104

novelty of invention, 7–9

overview, 15–16

patent recipient eligibility, 6–7

prior art

definition

implications, 22

Section 102(a)(1), 17–18

Section 102(a)(2), 19–21

exceptions

implications, 22–23

Section 102(b)(1), 21–22

Section 102(b)(2), 22

prior user rights, 29–31

supplemental examination and reissue, 31–33

third-party proceedings, 33–36

transition provisions in Sections 3(n)(1) and 3(n)(2), 27–29

American Fruit Growers v. Brogdex Co., 131

Angen, Inc. v. Chugai Pharmaceutical Co., 131

Angen, Inc. v. International Trade Commission, 197

ANDA. See Abbreviated New Drug Application

Anderson v. General Hospital Corp., 87

Anderson v. Piepper, 88

Andrx, 64

APO. See Australia Patent Office

Apotex, Inc. v. Wellcome Foundation, Ltd., 130

Arbitron, Inc. v. Kiefl, 87

Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 11, 93–95

Ariosa Diagnostics, Inc. v. Sequenom, Inc., 173

Arkansas Carpenters Health & Welfare Fund v. Boyer AG, 64


The Association for Molecular Pathology & Ors v. United States Patent and Trademark Office and Myriad Genetics, 157

Association for Molecular Pathology v. Unites States Patent and Trademark Office and Myriad Genetics, 241

Astra Aktiebolag v. Adrx Pharmaceuticals, Inc., 119, 124

Atlas Powder, Co. v. Ireco, Inc., 116

Australia Patent Office (APO)

patentable inventions, 151–153, 227–229

stem cell. See Stem cell patentability

Authorship, inventorship comparison, 88–89

### B


Bayh–Dole Act, 253

Bilski v. Kappos, 240

Biological Diversity Act, India, 248–250

Biotechnology Directive, European Patent Office

impact, 39–41

Biotechnology licensing agreement

enforcement and remedies, 263–264

intellectual property rights management

exclusive versus nonexclusive rights, 257

research and publication rights, 259–260

purpose, 254–255

structuring, 255–256

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Biotechnology licensing agreement (Continued) technology versus intellectual property, 254 term sheets, 256–258 types, 256 valuation and payment structures milestone payments, 262 practical aspects, 263 royalties, 260–262 upfront fees, 260

BMC Research, Inc. v. Paymentech, L.P., 186
Boston Scientific Corp. v. Johnson & Johnson, 96–97
Bounce, 128
Bowman v. Monsanto, 238
Brenner v. Manson, 95
Bristle case, 40, 220–221, 223
Bristle v. Greenpeace, 219, 222
Burroughs Welcome Co. v. Barr Laboratories, 6, 81, 90
Business method, patent eligibility, 240

C

D

E
Economic Espionage Act (EEA), 267 EEA. See Economic Espionage Act EFD. See Effective filing date Effective filing date (EFD), 17, 23, 25
Index

Eibel Process Co. v. Minnesota & Ontario Paper Co., 124
Eisai Co. Ltd. and Eisai, Inc. v. Dr. Reddys Laboratories, Ltd., 112
Electro-Craft Corp. v. Controlled Motion, Inc., 269
Eli Lilly & Co. v. Aradigm Corp., 84
Eli Lilly & Co. v. Medtronic, Inc., 48, 193
Eli Lilly v. Emisphere, 268
Embrey, Inc. v. Service Engineering Corp., 190–192
Embryonic stem cell. See Stem cell patentability
EMI Group North America, Inc. v. Cypress Semiconductor Corp., 5, 115
Enoxaparin, 196
EPC. See European Patent Convention
EPO. See European Patent Office
Ethicon, Inc. v. U.S. Surgical Corp., 80, 84–85
European Patent Convention (EPC)
  inventive step, 41–42
  member states and contracting states, 217–218
  novelty, 40–41
  patentable subject matter, 37–39
  research use exemption. See Experimental use exemption
  scope, 37
European Patent Office (EPO)
  amendment permissibility, 42–43
  Biotechnology Directive influences, 39–41
  Board of Appeal, 38
  gene patentability
    industrial applicability, 143–144
    inventive step, 145–148
    novelty, 144–145
    overview, 139–140
    patent eligibility, 140–143
    priority and added subject matter, 148–149
    prospects, 149–160
  limitation and revocation proceedings, 44–45
  opposition period for patents, 43–44
  stem cell. See Stem cell patentability
Ex parte Deuel, 106
Ex parte Francis Y.F. Lee, 109
Ex parte Theobold et al., 110
Ex parte Treacy et al., 110
Ex parte Francis Y.F. Lee, 109
Ex parte Perc, 108
Ex parte Treacey et al., 109
Experimental use exemption
  European Union
    France
      Bolar exemption, 206
      experimental use exemption, 206
    Germany
      Bolar provision, 204–205
      legal basis, 200–201
      reach and limitation, 202–204
      requirements, 201
  Italy, 207
  Netherlands, 207
  overview, 199–200
  Spain, 206–207
  United Kingdom
    Bolar exemption, 205–206
    experimental use exemption, 205
  Hatch–Waxman Act safe harbor provision
    biologics license applications, 197
    overview, 192–193
    postapproval experiments, 195–197
    preclinical experiments, 194–195
    research tools, 197–198
    scope of products, 193–194
    judicially created exemption
      business or commercial aims and failure, 192
      generic drug approvals, 190–192
      origins, 190
      overview, 189–190
      prospects, 198
  F
  Federal Trade Commission v. Watson Pharmaceuticals, 66
  Field v. Knowles, 87
  Fina Oil and Chemical Co. v. Ewen, 6, 88
  Forest Laboratories, Inc. v. Pillsbury Company, 3
  Frank’s Casing Crew & Rental Tools, Inc. v. PMR Technologies, Ltd., 6, 80, 90
  FTC. See Federal Trade Commission
  FTC v. Actavis, Inc., 70, 73
  Funk Brothers Seed Co. v. Kalo Inoculant Co., 180, 242
  G
  Garret Corp. v. United States, 84
  Gemstar-TV Guide Int’l, Inc. v. ITC, 6
  Genes. See DNA; specific genes
  Genetic diagnostic testing, federal regulation, 53–56
  Genetic Technologies Limited (GTG), 155
  Genetics Institute, Inc. v. Kirin-Amgen, Inc., 153
  Gibson-Homans Co. v. Wall-Tite Inc., 3
  GlaxoSmithKline v. Classen Immunotherapies, Inc., 53
  Global Patent Holdings, LLC v. Panthers BRHC LLC, 186
  Golden Hour Data Systems, Inc. v. ems Charts, Inc., 186
  Graham v. John Deere Co., 9, 107
  GTG. See Genetic Technologies Limited
  Gunter v. Stream, 81
  H
  Halliburton Energy Services, Inc. v. M-I LLC, 13
  Harvard/OncoMouse case, 38, 216

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

Hatch–Waxman Act, 47–53, 60–63, 71, 74, 175, 189, 192–198
Hess v. Advanced Cardiovascular Systems, Inc., 85
Hilmer doctrine, 19–20
Hobbs v. U.S. Atomic Energy Commission, 84
Hoechst Aktiengesellschaft v. Quigg, 18
Huang v. California Institute of Technology, 86
Human embryonic stem cell. See Stem cell patentability
HUMIRA, 95–96
Hybritech, Inc. v. Monoclonal Antibodies, Inc., 6, 11–12
corroboration, 88–89
experimentation and conceptions, 82–83
general concepts, 80–81
knockout gene, 89–90
overview, 79–80
quality of contribution, 84–86
timing of inventive contribution, 81–82
IP Innovation v. Red Hat, Inc., 86
IPR. See Inter partes review

J
Jamesbury Corp. v. United States, 80
Jansen v. Rexall Sundown, Inc., 111
Jedi Master Mixer (JMM), 27–29
JMM. See Jedi Master Mixer
Joint research agreement (JRA), 16, 24, 26
JRA. See Joint research agreement
Juicy Whip, Inc. v. Orange Bang, Inc., 5

K
Kimberly-Clark Corp. v. Proctor & Gamble Distributing Co., 84, 86
King Pharmaceuticals, Inc. v. Eon Labs, Inc., 120, 123
Kingdom of the Netherlands v. Council of the European Union, 141
Kirin-Amgen, Inc. v. Board of Regents of University of Washington and Genetics Institute, Inc., 153
KSR International Co. v. Teleflex, Inc., 9, 104–106

L
Lariscey v. U.S., 2
Limelight Networks, Inc. v. Akamai Technologies, Inc., 186
Lockwood v. American Airlines, Inc., 11
Loratadine, 119

M
Madey v. Duke University, 190, 192
MAGE-C1, 160
MAGE-C2, 160
Manny v. Garlick, 88
McKesson Technologies, Inc. v. Epic Systems Corp., 186
Medimmune Ltd. v. Novartis Pharmaceuticals, 146
Mehl/Biophile Int’l Corp. v. Milgram, 124

In re Antor Media Corp., 9
In re Bell, 105–106
In re Bergstrom, 131
In re Bergy, 210
In re Best, 124
In re Bilski, 121, 240
In re Cardizem CD Antitrust Litigation, 63–64
In re Ciprofloxacin Hydrochloride Antitrust Litigation, 66
In re Gosteli, 148
In re Grasselli, 116
In re Greenfield and Dupont, 110
In re Katz, 89
In re K-Dur Antitrust litigation, 62, 69
In re King, 117
In re Linder, 110
In re Marden, 131
In re May, 117
In re Montgomery, 122
In re Oelrich, 116
In re Omeprazole Litigation, 119, 123
In re Rijckaert, 124
In re Seaborg, 119
In re Spada, 117
In re Sullivan, 108
In re Tamoxifen Citrate Antitrust Litigation, 65
In re Tiffin, 110
 Inventorship
America Invents Act, 90
authorship comparison, 88–89
collaborations, 86–88
correction in pending applications, 90–91

80
111
16, 24, 26

27–29
238
238
141
153
9, 104–106

2
186
11
119
190, 192
160
160
88
4, 116, 179
186
146
124

286

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Memry Corp. v. Kentucky Oil Technology, 87
Merck & Co. v. Olin Mathieson Chemical Corp., 166
Merck KGaA v. Integra Lifesciences I, Ltd., 48–50, 194
Metabolite Laboratories, Inc. v. Laboratory Corp. of America Holdings, 117
Metallizing Engineering Co. v. Kenyon Bearing & Auto Parts Co., 18
Mikus v. Wachtel, 88
Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 50–53, 196–197
Monsanto Co. v. Kamp, 84
Monsanto Co. v. Stauffer Chemical Co., 205
Monsanto Technology v. Cargill International, 157
MPEP. See Manual of Patent Examining Procedure
Muniauction, Inc. v. Thomson Corp., 186
N
NAIL, 106
National Research Development Corporation v. Commissioner of Patents, 156–157, 227–228
Nonobviousness
DNA patents, 105–107
new indications for old drugs, 111
obvious versus nonobvious invention, 107–108
overview, 9–10, 103–105
person having ordinary skill, 107
small molecule obviousness, 111–113
unexpected results, 109–110
Novelty
European Patent Convention, 40–41
European Union patentability of genes, 144–145
patent, 7–9
O
Obviousness. See Nonobviousness
Oka v. Youssefeyeh, 82–83
Optical spray analyzer (OSA), 198
O'Reilly v. Morse, 85
Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc., 112
OSA. See Optical spray analyzer
P
p38. See NAIL
Pacesetter, Inc. v. Nervicon Co., 265
Pannu v. Iolab Corp., 6, 84
Parke-Davis & Co. v. H.K. Mulford Co., 128, 165
Paroxetine, 118
Patent
definition, 3–4
disclosure and claiming
claim requirements in Section 112, 12–13
overview, 10
specification requirements in Section 112, 10–12
eligible products, 5, 164
eligible recipients, 5–7
federal law and jurisdiction, 4–5, 235–236
nonobviousness. See Nonobviousness
novelty of invention, 7–9
research use exemption. See Experimental use exemption
self-replicating technologies, 235–242
stem cell. See Stem cell patentability
trade secret comparison, 3, 279–281
types, 4
Patent Cooperation Treaty (PCT), 19, 149
Patent Register, Canada
Comprehensive Economic and Trade Agreement, 77
generic products, 77
listing of patents
eligible claims and relevance requirements, 76–77
eligible drug submissions, 76
timing requirements, 76
Patented Medicines (Notice of Compliance) Regulations, 75–77
Patent Trial and Appeal Board (PTAB), 34–36
Patented Medicines (Notice of Compliance) Regulations. See Patent Register, Canada
Patents (Amendment) Act, India, 247–248
Patents Act, Australia, 159, 227, 229–231
PCT. See Patent Cooperation Treaty
Perricone v. Medicis Pharmaceutical Corporation, 121–122, 124
Personal Genomic Services (PGS), 24–25
PGR. See Post-grant review
PGS. See Personal Genomic Services
Pioglitazone, 112
Plant Variety Protection Act (PVPA), 236–238
Post-grant review (PGR), 33–36
Pozzoli v. BDMO, 145
Price v. Symsek, 88
Prior art
America Invents Act
definition
implications, 22
Section 102(a)(1), 17–18
Section 102(a)(2), 19–21
exceptions
implications, 22–23
Section 102(b)(1), 21–22
Section 102(b)(2), 22
avoidance in claim drafting, 186
Prohibition of Human Cloning Act, 230
Prometheus Labs, Inc. v. Mayo Collaborative Services, 5
Index

Protonix, 112
Proveris Scientific Corp. v. InnovaSystems, Inc., 198
PTAB. See Patent Trial and Appeal Board
Purdue Pharma LP v. Faulding, Inc., 11
PVPA. See Plant Variety Protection Act

R
Rapoport v. Dement, 111
The Regents of the University of California v. Eli Lilly & Co., 94
Restatement of the Law of Unfair Competition, 2
Rey-Bellet v. Engelhardt, 83
RGD peptides, 194
Richardson v. Suzuki Motor Co., 3
Roche Products, Inc. v. Bolar Pharmaceutical Co., 48, 190
Roche v. Bolar, 190–192
Rockwell Graphic Systems, Inc. v. DEV Industries, Inc., 268–269
Roundup Ready soybeans, 238
Rubin v. General Hospital Corp., 87

S
Sandt Technology, Ltd. v. Resco Metal & Plastics Corp., 87
Sanofi-Aventis v. Pfizer Inc., 83, 99–100
Sanofi-Synthelabo v. Apotex, 117, 124
Schering Corp. v. Geneva Pharmaceuticals, Inc., 116–118
Schering-Plough Corporation v. Federal Trade Commission, 60, 66
Seagate Technology, LLC v. Western Digital Corp., 265
SEC. See Service Engineering Corp.
Service Engineering Corp. (SEC), 191
Shatterproof Glass Corp. v. Libbey-Owens Ford Co., 84
Sherman Act, 63
SmithKline Beecham Corp. v. Apotex Corp., 118
State Street Bank & Trust v. Signature Financial Group, 239–240
Stem cell patentability
Australia
embryonic stem cell, 225–226
adult stem cell, 226–227
patentable inventions, 227–220
statutory conclusions, 229–231
prospects, 231–232
Europe
human embryonic stem cells, 218–224
law development, 216–218
overview, 215–216
prospects, 224
United States
changing landscape, 210–211
legal challenges, 213–214
statutory framework, 209–210
USPTO guidance, 211–213

T
Takeda Chemical Industries v. Alphapharm Pty, Ltd., 112
TBGRI. See Tropical Botanical Garden and Research Institute
TFP. See Tissue factor protein
Therasense Inc. v. Becton, Dickinson and Co., 13, 117
Tilghman v. Proctor, 124
Tissue factor protein (TFP), 147
TK. See Traditional knowledge
Tol-o-matic, Inc. v. Pruma Product-und Marketing Gesellschaft, 5
Topiramate, 112
Trade secret
Canada
duration of trade secret and loss of rights, 277
employees
absent agreement, 278–279
express agreement, 279
incoming employees and collaborations, 279
enforcement
damages, 281–282
injunction, 282
overview, 275–276
patent comparison, 279–281
rights, 277–278
trade knowledge comparison, 276–277
defenses, 271–274
definition, 1–2, 266–269
misappropriation, 269–271
overview, 265–266
patent comparison, 3
protection, 2–3
remedies, 271
Trade-Related Aspects of Intellectual Property Rights (TRIPS), 140–141, 150, 181, 217, 232, 243
Traditional knowledge (TK)
Biological Diversity Act, 248–250
overview, 243–244
Patents (Amendment) Act, 247–248
protection as property
defensive protection, 247–248
disclosure of geographic origin of biological material, 248
positive prevention, 246–247
prospects, 250
rationale, 245–246
Traditional Knowledge Digital Library, 247–248
traditional cultural expressions, 244–245
TRIPS. See Trade-Related Aspects of Intellectual Property Rights
Tropical Botanical Garden and Research Institute (TBGRI), 244–245
Trovan, Ltd. v. Sokymat SA, 88
23andMe, 24–26
U
Ultra-Precision Manufacturing, Ltd. v. Ford Motor Co., 86
Uniform Trade Secrets Act (UTSA), 2–3, 266–267, 270–271
Unilever PLC v. Proctor & Gamble, Inc., 128
United Carbon v. Binney & Smith Co., 12
University of Pittsburgh v. Hedrick, 81–82
University–industry partnership. See Biotechnology licensing agreement
Use of Embryos/WARF case, 219
USPTO. See U.S. Patent and Trademark Office
Utility patents
  living things, 237
  plants, 238
UTSA. See Uniform Trade Secrets Act

V
Valley Drug Company v. Geneva Pharmaceuticals, Inc., 64
Viagra, 111
Vioxx, 129
Voter Verified, Inc. v. Premier Election Solutions, Inc., 18

W
WARF. See Wisconsin Alumni Research Foundation
WARF/Thompson case, 40
WDR. See Written description requirement
Wells v. Ortho Pharmaceutical Corp., 129
Windsurfing v. Tabaur Marine, 145
Wisconsin Alumni Research Foundation (WARF), 213–214
Woodland Trust v. FlowerTree Nursery, Inc., 88
Written description requirement (WDR)
  Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 93–95
  Boston Scientific Corp. v. Johnson & Johnson, 96–97
  Centocor Ortho Biotech, Inc. v. Abbott Laboratories, 95–96
  evolution, 100–101
  Sanofi-Aventis v. Pfizer Inc., 99–100
  Wyeth v. Abbott Laboratories, 97–98
  Wyeth v. Abbott Laboratories, 97–98

Y
Yield Dynamics, Inc. v. Tea Systems Corp., 269
Yvonne D’Arcy v. Myriad Genetics Inc. & Anor, 157